7α-Hydroxy-DHEA
|
| |
| Names | |
|---|---|
|
IUPAC name
3β,7α-Dihydroxyandrost-5-ene-17-one
| |
|
Systematic IUPAC name
(3aS,3bR,4S,7S,9aR,9bS,11aS)-4,7-Dihydroxy-9a,11a-dimethyl-2,3,3a,3b,4,6,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-1-one | |
| Other names
7α-OH-DHEA; Androst-5-en-3β,7α-diol-17-one
| |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
|
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C19H28O3 | |
| Molar mass | 304.430 g·mol−1 |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
7α-Hydroxydehydroepiandrosterone (7α-hydroxy-DHEA; 7α-OH-DHEA), also known as 3β,7α-dihydroxyandrost-5-ene-17-one, is an endogenous, naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA) that is formed by CYP7B1 (steroid 7α-hydroxylase) in tissues such as the prostate gland and by CYP3A4 in the liver. The major metabolic pathway of DHEA outside the liver is via 7-hydroxylation into 7α-OH-DHEA and 7β-OH-DHEA. 7α-OH-DHEA has weak estrogenic activity, selectively activating the estrogen receptor ERβ. In addition, 7α-OH-DHEA may be responsible for the known antiglucocorticoid effects of DHEA.
Serum levels of 7α-OH-DHEA have been found to be significantly elevated in patients with Alzheimer's disease. It is unclear what significance this may have, if any.
7α-OH-DHEA is on the World Anti-Doping Agency list of prohibited substances in sporting.
See also
External links
| ER |
|
||||||
|---|---|---|---|---|---|---|---|
| GPER |
|
||||||
| GR |
|
||||||||
|---|---|---|---|---|---|---|---|---|---|